6919
KEL CORPORATION
6919
KEL CORPORATION
6919
KEL CORPORATION
FDA IND Clearance for CBL-0201WR-Caliway has cleared its Investigational New Drug application for CBL-0201WR, a Phase 2 trial evaluating CBL-514 in combination
KEL (6919) has released its financial results, reporting net sales of 3,524 million yen (a 19.7% increase year-on-year) and operating income of 80 million yen (a significant 427.5% surge). Furthermore